| Company Name: |
shlmai |
| Tel: |
021-67680335 13052188602 |
| Email: |
sale1@shlmai.net |
|
| Product Name: | PAI-1 | | Synonyms: | ARMAPE;MOUSE PAI-1;MOUSE PLASMINOGEN ACTIVATOR INHIBITOR-1;PAI-1;PAI-1, HUMAN;PAI-1, MOUSE;PAI-1, MUTANT, MOUSE;PAI-1, RAT | | CAS: | 31514-41-7 | | MF: | C27H47N9O9S | | MW: | 673.78 | | EINECS: | | | Product Categories: | enzyme | | Mol File: | Mol File |  |
| | PAI-1 Chemical Properties |
| storage temp. | -70°C | | form | liquid |
| | PAI-1 Usage And Synthesis |
| Biological Activity | Cell permeable: no', 'Primary Target
Tissue plasminogen activator (tPA) and urokinase (uPA)', 'Product does not compete with ATP.', 'Reversible: no | | Enzyme inhibitor | This 402-residue serine protease inhibitor, or serpin (MW = 45074 g/mol; Abbreviation: PAI-1) binds to and inhibits plasminogen activators-tissuetype plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). This inhibition reduces plasmin production and suppresses dissolution of fibrin clots. Elevated PAI-1 levels correlate with an increased cardiovascular disease risk, a behavior that has also been linked to obesity and metabolic syndrome. Pharmacological suppression of PAI-1 is a likely way to prevent or treat vascular disease. Reduced PAI-1 levels may result in increased fibrinolysis and an associated bleeding diathesis. PAI-1 was initially identified in the 1980s, and the first reported case of PAI-1 deficiency appeared in 1989. Unambiguous proof that PAI-1 deficiency as a cause of a bleeding disorder has been rare, but use of selective PAI inhibitors (See PAI-749) may clarify this point. Because of lack of standardized commercially available PAI-1 activity assay sensitive in the lowest range, the true prevalence of this rare condition has yet to be established. |
| | PAI-1 Preparation Products And Raw materials |
|